Wear and migration are not influenced by head size in a vitamin E-infused highly cross-linked polyethylene acetabular cup.


Journal

Orthopaedics & traumatology, surgery & research : OTSR
ISSN: 1877-0568
Titre abrégé: Orthop Traumatol Surg Res
Pays: France
ID NLM: 101494830

Informations de publication

Date de publication:
02 2021
Historique:
received: 04 06 2019
revised: 19 03 2020
accepted: 24 03 2020
pubmed: 2 1 2021
medline: 25 6 2021
entrez: 1 1 2021
Statut: ppublish

Résumé

Aseptic loosening and periprosthetic osteolysis are frequent complications in total hip arthroplasty requiring revision surgery. Highly cross-linked polyethylene (HXLPE) implants have improved wear resistance, permitting larger femoral heads. However, such implants may experience surface cracking, mechanical failure, and oxidative damage. Vitamin E-infused HXLPE (VEPE) implants were therefore developed to reduce oxidation without compromising mechanical strength. We addressed the following questions: (1) Does femoral head size affect the midterm annual polyethylene wear rates of VEPE acetabular cups? (2) Does femoral head size affect the midterm migration rates of VEPE acetabular cups? (3) Are clinical outcomes affected by femoral head size? Annual wear rate, migration rate, and clinical outcomes of VEPE acetabular cups are independent of femoral head size. This was a prospective, multicentre, observational study of patients that underwent total hip arthroplasty. Hips were grouped according to the size of femoral head implanted (28 mm, 32 mm, and 36 mm). We determined annual wear rate and migration rate of VEPE acetabular cups using the Einzel-Bild-Röntgen-Analyse software. Clinically, we assessed the Harris Hip Score and visual analog score for pain and satisfaction. We followed 253 patients (267 hips) for a mean of 55.0±20.6 months in the 28 mm, 46.2±21.4 months in the 32 mm, and 43.8±22.6 months in the 36 mm group. The annual wear rate was 0.025 mm per year from 1 year to the last follow-up and remained similar between the groups (p>0.05). Also, mean two-dimensional migration rates did not exceed 0.05 mm from 2 years to the last follow-up and remained similar between the groups (p=0.355). Finally, clinical outcomes also did not differ between the groups (p>0.05). Two patients required revision surgery. Femoral head size did not influence midterm annual wear rate, migration rate, and clinical outcomes of VEPE acetabular cups. Furthermore, wear and cup migration rates were below the reported values leading to osteolysis and aseptic loosening. Nevertheless, studies with extended follow-up periods will be necessary to confirm these results in the long term. IV.

Sections du résumé

BACKGROUND
Aseptic loosening and periprosthetic osteolysis are frequent complications in total hip arthroplasty requiring revision surgery. Highly cross-linked polyethylene (HXLPE) implants have improved wear resistance, permitting larger femoral heads. However, such implants may experience surface cracking, mechanical failure, and oxidative damage. Vitamin E-infused HXLPE (VEPE) implants were therefore developed to reduce oxidation without compromising mechanical strength. We addressed the following questions: (1) Does femoral head size affect the midterm annual polyethylene wear rates of VEPE acetabular cups? (2) Does femoral head size affect the midterm migration rates of VEPE acetabular cups? (3) Are clinical outcomes affected by femoral head size?
HYPOTHESIS
Annual wear rate, migration rate, and clinical outcomes of VEPE acetabular cups are independent of femoral head size.
PATIENTS AND METHODS
This was a prospective, multicentre, observational study of patients that underwent total hip arthroplasty. Hips were grouped according to the size of femoral head implanted (28 mm, 32 mm, and 36 mm). We determined annual wear rate and migration rate of VEPE acetabular cups using the Einzel-Bild-Röntgen-Analyse software. Clinically, we assessed the Harris Hip Score and visual analog score for pain and satisfaction.
RESULTS
We followed 253 patients (267 hips) for a mean of 55.0±20.6 months in the 28 mm, 46.2±21.4 months in the 32 mm, and 43.8±22.6 months in the 36 mm group. The annual wear rate was 0.025 mm per year from 1 year to the last follow-up and remained similar between the groups (p>0.05). Also, mean two-dimensional migration rates did not exceed 0.05 mm from 2 years to the last follow-up and remained similar between the groups (p=0.355). Finally, clinical outcomes also did not differ between the groups (p>0.05). Two patients required revision surgery.
DISCUSSION
Femoral head size did not influence midterm annual wear rate, migration rate, and clinical outcomes of VEPE acetabular cups. Furthermore, wear and cup migration rates were below the reported values leading to osteolysis and aseptic loosening. Nevertheless, studies with extended follow-up periods will be necessary to confirm these results in the long term.
LEVEL OF EVIDENCE
IV.

Identifiants

pubmed: 33384276
pii: S1877-0568(20)30185-7
doi: 10.1016/j.otsr.2020.03.030
pii:
doi:

Substances chimiques

Vitamin E 1406-18-4
Polyethylene 9002-88-4

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102644

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

Simon Comtesse (S)

Mathys Ltd Bettlach, Robert-Mathys Strasse 5, 2544 Bettlach, Switzerland.

Arthur de Gast (A)

Diakonessenhuis Utrecht, Bosboomstraat 1, 3582 KE Utrecht, Netherlands; Clinical Orthopedic Research Centre midden-Nederland, Diakonessenhuis Zeist, Jagersingel 1, 3707 HL Zeist, Netherlands.

Philipp Rehbein (P)

St. Josefs-Hospital Wiesbaden, Beethovenstraße 20, 65189 Wiesbaden, Germany.

Gary French (G)

Ormiston Hospital, 125, Ormiston Road, Flat Bush, 2016 Manukau, New Zealand.

Naeder Helmy (N)

Bürgerspital Solothurn, Schöngrünstrasse 42, 4500 Solothurn, Switzerland.

Roland Becker (R)

Zentrum für Orthopädie und Unfallchirurgie, Endoprothesenzentrum West-Brandenburg, Medizinische Hochschule Theodor Fontane, 14776 Brandenburg/Havel, Germany.

Martin Dominkus (M)

Orthopädisches Spital Speising, Speisinger Straße 109, 1130 Wien, Austria; Sigmund-Freud University, Campus Prater Freudplatz 1, 1020 Wien, Austria.

Martin Beck (M)

Luzerner Kantonsspital, Spitalstrasse, 6000 Luzern, Switzerland. Electronic address: martin.beck@luks.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH